Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line
Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease
Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.
Objective: We aimed to investigate whether depression is associated with a higher risk of developing impulse control disorders (ICD) in Parkinson´s disease (PD) patients and…Novelty Seeking: A Narrative Review
Objective: To explore novelty seeking (NS) as a construct, in both its adaptive and maladaptive roles, in order to provide insight into the cognitive and…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…REM sleep behavior disorder in Parkinson´s Disease: a risk factor for Impulse Control Disorders.
Objective: We aimed to analyze de association between REM sleep behavior disorder (RBD) and impulse control disorders (ICD) in Parkinson´s disease (PD) patients and in…The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis
Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy
Objective: To report a patient with progressive supranuclear palsy (PSP) in whom an impulse control disorder (ICD) was triggered by a dopaminergic therapy. Background: ICDs…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »